New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
13:47 EDTREGN, SNYRegeneron price target raised to $382 from $362 at Roth Capital
Roth Capital raised its price target on Regeneron (REGN) after the company and partner Sanofi (SNY) presented the full data set from the ODYSSEY MONO study, along with data supporting the potential for once per month dosing with alirocumab. Roth noted that Sanofi is guiding to filing for approval for the drug in 2016.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
08:28 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
08:16 EDTSNYPieris Pharmaceuticals achieves payment milestone in Sanofi collaboration
Subscribe for More Information
November 29, 2015
19:37 EDTSNYSanofi working with Lazard to explore sale of animal health unit, Reuters says
Lazard (LAZ) is working with Sanofi (SNY) to prepare a sale or listing of the company's Merial animal health division, which could value the unit at up to $12.7B, reports Reuters, citing sources. The investment bank is expected to land the lead advisory role for the potential deal, sources told Reuters, which added that the sale would play a "pivotal role" in getting Sanofi "back on track." Reference Link
November 24, 2015
05:23 EDTREGN, SNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use